| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Cell Therapies | Nervous System | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Cell Therapies | Nervous System | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Cell Therapies | Nervous System |
Recent Updates
Recently added Catalysts
Autolus Therapeutics plc$1.61
-0.08 (-4.73%)
D 36Pipeline Score Overvalued Biotech · Commercial
Market Cap
465.77 M
EPS
-1.09
P/E Ratio
-1.61 $
Value Trade
3.40 M
SEC Financials
Q1 2026Dilution Risk
Revenue
26.22 M
R&D Expenses
21.21 M
Operating CF
-65.32 M
Total Assets
527.07 M
Total Liabilities
418.24 M
Equity
108.83 M
D/E Ratio
12,345
7.59 %
Week
11.11 %
1 Month
3.03 %
3 Month
38.21 %
6 Month
-73.81 %
5 Year
-93.93 %
All Time
Cash Data
Cash Position
229.43 M
Monthly Burn
21.77 M
Runway
8.6 mo
Burn Trend
StableSEC Filing
May 14, 2026
Overview
Volume
1.35 M
52 Week Range
1.18 - 2.70
% held by Insiders
9.63 %
% held by Institutions
46.53 %
Enterprise Value
603.97 M
Total Shares
266.16 M
Short %
5.6 %
Float Shares
240.52 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Autolus Therapeutics plc
255Total events
9Upcoming
62Tier-1 (high impact)
2018 – 2028Coverage
Upcoming catalysts 9
2027-H1
T2Enrollment Complete
CATULUS Phase 2 trial expected to be fully enrolled in first half of 2027
Event history 246
Jun 12, 2026
Jun 3, 2026
Jun 2, 2026
◆Oral PresentationPresentation
William Blair 46th Annual Growth Stock Conference presentation
Jun 2026
◆Manufacturing MilestoneCMC / Inspection
Detailed update on manufacturing life cycle plan expected in mid-2026
May 30, 2026
◆Oral Presentationobe-celPresentation
Rapid Oral Abstract presentation at ASCO 2026 on obe-cel in B-ALL with extramedullary disease
relapsed/refractory B-cell acute lymphoblastic leukemiasource ↗
May 21, 2026
◆Abstractobe-celPresentation
Abstract 6517 published for ASCO 2026 on obe-cel in B-ALL with extramedullary disease
relapsed/refractory B-cell acute lymphoblastic leukemiasource ↗
May 14, 2026
May 14, 2026
▲RMATobe-celDesignation
FDA granted RMAT designation for obe-cel in pediatric r/r B-ALL
pediatric relapsed or refractory B-cell precursor ALLsource ↗
May 14, 2026
●Enrollment Updateobe-celTrial
Phase 2 portion of CATULUS trial enrolling
pediatric relapsed or refractory B-cell precursor acute lymphoblastic leukemiasource ↗
Drug Pipeline Intelligence
D36
Pipeline Score $316M
Pipeline ValueOvervalued
Valuation Signal4
Drugs Scored0.7x
rNPV / MCap Top 50%
Micro Cap (rank 457 of 912)
Percentile RankAutolus Therapeutics plc faces pipeline headwinds (36/100), with $1.7B risk-adjusted pipeline value, led by Obecabtagene autoleucel in Progressive Multiple Sclerosis (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Obecabtagene autoleucel Monoclonal antibody | Lupus Nephritis | Phase 2 | NCT07053800 | 46% | $621M | RECRUITING | 35 | VERY_FAST | D (38) | Oct 1, 2029 | HIGH_RISK | MEDIUM May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
obe-cel RMAT | relapsed/refractory B-ALL and extramedullary disease | Phase 1b/2 | 2026-05-21 | overall response rate: 59%; median duration of response: 42.6 months Read More | Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026 Read More | |
obe-cel RMAT | relapsed/refractory B-ALL and extramedullary disease | Phase 1b/2 | 2026-05-21 | overall response rate: 59%; median duration of response: 42.6 months Read More | Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026 Read More | |
obe-cel RMAT | relapsed/refractory B-ALL and extramedullary disease | Phase 1b/2 | 2026-05-21 | overall response rate: 59%; median duration of response: 42.6 months Read More | Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in AUTL
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
AUTL Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
AUTLAutolus Therapeutics Receives Prix Galien UK Award
Autolus Therapeutics has been awarded the 2026 Prix Galien UK Award for Best Biotechnology Product. This prestigious recognition, awarded by a committee of UK healthcare experts, underscores the company's commitment to developing innovative T cell therapies. Dr. Martin Pule, the company's founder, expressed pride in the award, which acknowledges the dedication of their teams in advancing treatment options for patients.
Read more →AUTLautoluannualreporta Registered Number 11185179 (England & Wales) Annual Report and financial statements for the year ended 31 December 2025 for Autolus Therapeutics plc Introduction and Contents Autolus Therapeutics plc
Autolus Therapeutics plc has released its Annual Report for 2025, highlighting significant advancements in its T cell therapies, particularly AUCATZYL, which received FDA approval for treating adult patients with relapsed/refractory B-ALL. The company successfully launched AUCATZYL in the U.S. and U.K., though its entry into the EU market remains postponed with no sales expected in 2026. The report also conveyed positive safety data for obe-cel in pediatric patients, indicating consistent safety with low rates of serious side effects. However, concerns exist regarding the halted EU launch and market entry strategies.
Read more →AUTLAutolus Therapeutics to Participate in Upcoming Investor Conferences
Autolus Therapeutics will participate in two investor conferences in June 2026. CEO Dr. Christian Itin will present at the William Blair Annual Growth Stock Conference and the Jefferies Global Healthcare Conference. Webcasts of the presentations will be available on the company's website, with replays archived for 90 days.
Read more →AUTLAutolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026
Autolus Therapeutics announced an abstract publication for the ASCO Annual Meeting, detailing the efficacy of obe-cel in treating patients with relapsed/refractory B-ALL and extramedullary disease. The data indicates a 59% overall response rate and a median duration of response of 42.6 months, suggesting promising potential for this treatment. The findings stem from a post-hoc analysis of the Phase Ib/II FELIX study.
Read more →AUTL▼ -7%on this news
Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
Autolus Therapeutics reported strong financial results for Q1 2026, with net product revenue of $26.2 million from AUCATZYL. The company achieved a positive gross margin for its acute lymphoblastic leukemia (ALL) business and is expanding its market presence in the UK. However, it also reported a net loss of $71.6 million and announced a workforce reduction to improve operational efficiency.
Read more →AUTL▼ -7%on this news
autlex-991pr140526 Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
Autolus Therapeutics reported robust financial results for the first quarter of 2026, highlighting a net product revenue of $26.2 million for AUCATZYL, driven by successful market launches in the US and UK. The company achieved a positive gross margin for its acute lymphoblastic leukemia business, alongside ongoing clinical trials for multiple new indications. Despite these advancements, Autolus recorded a net loss of $71.6 million and announced a strategic plan to reduce its workforce by about 13% to improve operational efficiency. The company remains optimistic about its future outlook, projecting significant growth in revenue for the year.
Read more →AUTLAutolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026
Autolus Therapeutics plc will announce its first quarter 2026 financial results on May 14, 2026. The company will host a conference call at 8:30 am EDT to discuss these results and provide a business update. Participants must pre-register for the call. Autolus specializes in next-generation T cell therapies for cancer and autoimmune diseases.
Read more →AUTLAutolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction Initiative focused on driving gross profit margin and path to profitability for the ALL business Company will reduce headcoun
Autolus Therapeutics announced a strategic initiative to improve operational efficiency by reducing its workforce by approximately 13%. This restructuring is projected to save around $15 million annually starting in 2027, although it will result in one-time restructuring charges estimated at $8 million. The company continues to express confidence in its cash reserves to support operations through late 2027. CEO Dr. Christian Itin highlighted the solid performance of AUCATZYL as a catalyst for ongoing growth and profitability.
Read more →AUTLAdvancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition
The biotechnology sector is shifting towards valuing scientific progress as a financial asset rather than merely a cost. This change is supported by fair-value accounting principles that allow companies to reflect clinical advancements in their financial reports. As drug candidates advance through clinical stages, their valuations increase significantly, attracting institutional investors focused on pipeline-driven value.
Read more →AUTL▲ +9.6%on this news
allinvestoreventap Spotlight on the Acute Lymphoblastic Leukemia (ALL) Business
Autolus Therapeutics held an investor event on April 8, 2026, focusing on their product AUCATZYL for treating acute lymphoblastic leukemia (ALL). The event addressed the significant unmet medical need in treating adult patients with relapsed or refractory B-ALL. Key presentations outlined both the potential benefits and serious safety concerns related to AUCATZYL, including risks of severe infections and neurological toxicities. Future prospects for AUCATZYL depend on successful commercialization and navigating regulatory challenges.
Read more →AUTL▼ -6.2%on this news
autlex-991pr270326 Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
Autolus Therapeutics reported its financial results for Q4 and the full year of 2025, revealing a net revenue of $23.3 million for the fourth quarter. The company successfully launched AUCATZYL in the UK after a positive NICE evaluation and is expanding the product's indications. Real-world data from the ROCCA consortium reaffirmed the therapy's efficacy and safety. Looking ahead, Autolus estimates 2026 revenue between $120 million to $135 million and anticipates shifting to a positive gross margin as manufacturing efficiencies improve.
Read more →AUTL▼ -17.1%on this news
autlex-991pr120126 Autolus Therapeutics Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Net Product Revenue, Pipeline Advancements and Outlook for 2026
Autolus Therapeutics has announced preliminary unaudited net product revenues for AUCATZYL, expecting approximately $24 million in Q4 2025 and $75 million for the entire year. The company has high expectations for 2026, projecting revenues between $120 million and $135 million driven by positive clinical data and a successful product launch. Autolus also provided updates on ongoing trials for pediatric oncology and autoimmune diseases, which show promising results and will likely advance to Phase 2 studies. The company's focus for 2026 includes optimizing manufacturing operations and expanding the capabilities of AUCATZYL in various indications.
Read more →AUTLautlex-991pr011225 1 Autolus Therapeutics Appoints Ryan Richardson to Board of Directors LONDON & Gaithersburg, MD
Autolus Therapeutics plc has appointed Ryan Richardson to its Board of Directors, leveraging his over 20 years of strategy and corporate development experience in healthcare and investment banking. As the company enters a new growth phase, Richardson's expertise is expected to aid in expanding the reach of its leading T cell therapy, obe-cel. The CEO, Dr. Christian Itin, expressed optimism about Richardson's contributions to maximize commercial opportunities. Richardson's background includes significant roles at BioNTech, where he was instrumental in its transition to a commercial-stage company.
Read more →AUTL▼ -9.3%on this news
autlex-991pr121125 Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates
Autolus Therapeutics has reported its financial results for Q3 2025, highlighting net product revenues of $21.1 million and deferred revenues of $7.6 million. The company achieved 60 fully activated treatment centers in the U.S., exceeding its target, and reported promising efficacy data for its product obe-cel in pediatric acute lymphoblastic leukemia and severe lupus nephritis. Despite a temporary lag in sales linked to reimbursement policy changes, expectations for future growth remain high as the company prepares for pivotal studies and continues to optimize its operations.
Read more →AUTL▼ -12.8%on this news· ran to -28% by day 3
autlex-991pr120825 Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates
Autolus Therapeutics reported its Q2 2025 financial results, highlighting a net product revenue of $20.9 million. The company received conditional marketing authorization for its drug AUCATZYL in the UK and EU. Notably, recent data from the FELIX trial showcased the potential of obe-cel for long-term remission in patients with r/r B-ALL. Despite positive revenue and clinical trial progresses, Autolus faces challenges with NICE's funding recommendations, a halted launch in Germany, and increased operational losses.
Read more →AUTL▲ +9.1%on this news· ran to +29% by day 3
autolusannualreport statement of liabilities parent company
autolusannualreport statement of liabilities parent company
Read more →AUTL▲ +9.8%on this news
autlex-991pr080525 Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates
Autolus Therapeutics reported its first quarter 2025 financial results, highlighting a net product revenue of $9.0 million for AUCATZYL. The company received conditional marketing authorization for AUCATZYL from the MHRA for treating patients with relapsed or refractory B-ALL. Preliminary positive data from the Phase 1 CARLYSLE trial for systemic lupus erythematosus was also discussed, with plans for further pivotal trials in lupus nephritis and multiple sclerosis. Despite these advances, Autolus continues to face significant financial losses and rising operational costs.
Read more →AUTL▼ -13.7%on this news
patient enrollment delays or otherwise; Autolus' ability to successfully demonstrate the safety and efficacy of its product candidates and gain approval of its product candidates on a timely basis, if at all; competition
Autolus has reported several risks and uncertainties that could affect its clinical trials and the approval of its product candidates. These include potential delays in patient enrollment and concerns about the safety and efficacy of AUCATZYL, particularly in relation to adverse reactions and competition in the market. Additionally, the company faces challenges in maintaining regulatory approval and advancing into additional indications. Risks related to macroeconomic conditions further complicate Autolus' operational landscape.
Read more →AUTLautlex-991cp130125 Developing Next Generation Programmed T Cell Therapies January 2025 Autolus.com Disclaimer These slides contain forward-looking statements within the meaning of the "safe harbor" provisions of the Priv
Autolus Therapeutics is advancing its next-generation programmed T cell therapies, with a focus on the obe-cel program. The company has received FDA approval for AUCATZYL, its first CD19 CAR T cell therapy, which is indicated for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (B-ALL). With significant growth prospects ahead, the firm aims to expand its pipeline and explore the potential of its therapies in additional disease settings. However, future success depends on navigating various risks associated with clinical trial outcomes and safety concerns.
Read more →AUTL▼ -5.1%on this news
autlex-991pr121124 Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates
Autolus Therapeutics announced its financial results for the third quarter of 2024, highlighting the FDA approval of AUCATZYL for adult B-ALL treatment. This approval prompted a $30 million milestone payment from Blackstone. The company reported a net loss of $82.1 million for the quarter and an increase in operating expenses compared to the previous year. Ongoing clinical studies and a strong cash position are positioned to support future growth and pipeline development.
Read more →AUTL▼ -7.7%on this news· ran to -19% by day 3shared move
autlex-991pr081124 1 Autolus Therapeutics Announces FDA Approval of AUCATZYL (obecabtagene autoleucel - obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) - AUCATZYL is the first
Autolus Therapeutics has received FDA approval for AUCATZYL (obecabtagene autoleucel) to treat adults with relapsed or refractory B-cell acute lymphoblastic leukemia. This CAR T therapy is notable for being the first approved without requiring a REMS program, highlighting its safety profile. Clinical trial data demonstrated a 63% overall complete remission rate in efficacy evaluable patients, along with a median duration of remission of 14.1 months. The approval paves the way for AUCATZYL's availability in the U.S., with distribution managed by Cardinal Health.
Read more →AUTLautlex-991cp260924 Developing Next Generation Programmed T Cell Therapies September 2024 Autolus.com EX-99.1 Disclaimer These slides contain forward-looking statements within the meaning of the "safe harbor" provisions o
Autolus Therapeutics is advancing its CAR T cell therapy candidate, obe-cel, which showed a promising 78% overall response rate in the pivotal FELIX trial for relapsed/refractory adult acute lymphoblastic leukemia (ALL). With regulatory submissions pending and a strong cash position of $706 million, the company is well-positioned for growth and expansion into additional malignancies. However, uncertainties remain regarding the future success of clinical trials and the potential for timely product approvals. Overall, the development of obe-cel could lead to significant advancements in CAR T therapies for patients with challenging cancer diagnoses.
Read more →AUTLautlex-991pr190924 1 Autolus Therapeutics announces appointment of Matthias Will, M.D. as Chief Development Officer LONDON
Autolus Therapeutics has appointed Dr. Matthias Will as Chief Development Officer, effective September 30, 2024. Dr. Will brings extensive experience in pharmaceutical product development, having held significant roles at various biotechnology companies. His leadership is expected to advance the company's development of its lead product, obe-cel, and expand its portfolio into other oncology and autoimmune disease areas. The appointment comes as Autolus prepares for potential commercialization milestones and regulatory submissions for obe-cel, aimed at treating relapsed/refractory adult B-ALL.
Read more →AUTL▼ -9.5%on this news
autlex-991pr080824 Autolus Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates
Autolus Therapeutics reported strong financial results for Q2 2024, highlighting a significant cash position of $705.9 million. The company is progressing towards the U.S. commercial launch of its lead product, obe-cel, with a PDUFA date set for November 16, 2024. Promising data from the FELIX Phase 1b/2 study indicate durable patient responses, though the organization faces increased operating expenses and a substantial net loss. The ongoing regulatory review process for market authorization applications is a pivotal point for the company.
Read more →AUTLRegistered Number 11185179 (England & Wales) Annual Report and financial statements for the year ended 31 December 2023 for Autolus Therapeutics plc Introduction and Contents Autolus Therapeutics plc (the "Company", "G
Autolus Therapeutics plc has released its annual report for the fiscal year ended December 31, 2023. The report outlines the company's operations in developing advanced programmed T cell therapies tailored for cancer and autoimmune diseases. Autolus aims to leverage its proprietary technologies to produce therapies that can potentially outperform existing treatments, providing substantial benefits, including the possibility of cures for certain patients. Their production processes focus on safety and effectiveness through innovative engineering approaches.
Read more →AUTLAutolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call LONDON
Autolus Therapeutics plc has announced a delay in its earnings release and conference call originally scheduled for May 14, 2024. The company intends to file a Form 12b-25 with the SEC to obtain an extension for filing its Q1 2024 10-Q report. The new deadline for this report is set for May 20, 2024, and a rescheduled conference call will take place on May 17, 2024, to discuss financial results and provide a business update.
Read more →AUTLectranscript150324 Event ID: 138235356103 Event Name: Q4 2023 Autolus Therapeutics PLC Earnings Call Event Date: 2024-03-14T12:30:00 UTC P: Operator;; C: Olivia Manser;Autolus Therapeutics PLC;Investor Relations C: Chris
Autolus Therapeutics recently held an earnings call to highlight the company's operational and financial results for 2023. This call featured key figures such as CEO Christian Itin and CFO Rob Dolski, who discussed important transactions including a collaboration with BioNTech, aimed at advancing their lead program, obe-cel, and other candidates. The collaboration is expected to enhance Autolus' capabilities and market readiness, presenting significant financial backing and strategic opportunities for future growth. The company also reported promising clinical trial results and emphasized their strengthened cash position.
Read more →AUTLDisclaimer Developing Next Generation Programmed T Cell Therapies These slides contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995
Autolus Therapeutics is advancing its next-generation programmed T cell therapies, focusing on its lead candidate, obe-cel, for treating cancers such as relapsed/refractory acute lymphoblastic leukemia (ALL). The company is engaged in a strategic collaboration with BioNTech, which provides financial support and opportunities for co-development. Despite promising clinical results, challenges remain in terms of timely approvals and patient enrollment in trials. The company plans to expand its pipeline and enhance manufacturing capabilities to facilitate the commercialization of its therapies.
Read more →AUTL▼ -5.1%on this newsshared move
Autolus Announces Pricing of Underwritten Offering LONDON 8 February 2024 Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today
Autolus Therapeutics plc has announced the pricing of an underwritten offering in the United States, comprising 58,333,336 American Depositary Shares at a price of $6.00 per ADS, aiming for total gross proceeds of $350 million. The funds will be utilized to advance their clinical programs, particularly the obe-cel therapy, and to bolster their commercial capabilities. The offering is expected to close on February 12, 2024, pending customary conditions. Jefferies LLC and Truist Securities are serving as joint bookrunners for this offering.
Read more →AUTL▼ -5.1%on this newsshared move
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs Strategic alliance leverages manufacturing and commercial infrastructure as well as technology w
BioNTech and Autolus have announced a strategic collaboration to advance their autologous CAR-T cell therapy programs. This partnership includes a $200 million investment from BioNTech into Autolus, aimed at leveraging both companies' technologies to enhance cancer treatment options. The agreement also involves a license and option agreement that will facilitate the commercialization of several cancer therapies, pending regulatory approvals. This collaboration is seen as a significant step forward in addressing unmet medical needs in oncology.
Read more →AUTL▲ +14.9%on this news· ran to +39% by day 1
of this Report on Form 6-K. 14
Autolus Therapeutics plc has filed its Form 6-K with the SEC detailing its financial condition and operational results. The company has reported a net loss of $131.2 million for the nine months ended September 30, 2023, contributing to an accumulated deficit of $801.4 million. Key updates include planned submissions for the biologics license application for its programmed T cell therapies, obe-cel, targeting relapsed refractory adult Acute Lymphoblastic Leukemia and the development of therapies for autoimmune diseases. Despite ongoing operational losses, the company has a robust pipeline and sufficient cash reserves projected to support operations for the next year.
Read more →AUTLof this Report on Form 6-K. 15
Autolus Therapeutics plc released its Form 6-K discussing financial conditions and operational results for H1 2023. The company continues to develop advanced T cell therapies for cancer, with promising data for obe-cel presented at key conferences. Despite reporting significant operating losses, their ongoing collaborations and cash reserves position them to sustain operations in the near term. The company is also on track with its new manufacturing facility, which is crucial for scaling production.
Read more →AUTLannualreportandacco
annualreportandacco
Read more →AUTL▼ -7.3%on this newsshared move
pressreleasedatedj Autolus Therapeutics Presents Positive Results from Pivotal Phase 2 FELIX study in adult r/r B-ALL at ASCO
Autolus Therapeutics announced encouraging results from its pivotal Phase 2 FELIX study, evaluating the safety and efficacy of its investigational therapy obe-cel in adult patients with relapsed/refractory B-cell Acute Lymphoblastic Leukemia (B-ALL). The study reported that 76% of patients achieved a complete response or CRi, with a notable 61% maintaining remission without additional therapies at a median follow-up of 9.5 months. With a potentially best-in-class tolerability profile, the treatment exhibited low rates of severe side effects, although some significant adverse events were noted. Autolus plans to submit a Biologics License Application for obe-cel by the end of 2023.
Read more →AUTLof this Report on Form 6-K. 12
Autolus Therapeutics plc has provided an update on its financial condition and operations as part of its Report on Form 6-K. The company has reported significant operating losses and an accumulation of substantial debt, totaling $710 million. Despite these challenges, Autolus is progressing with plans for its lead T cell therapy, obe-cel, which is set for a BLA submission by the end of 2023. Additionally, they are on track with their new manufacturing facility in the UK, with operations expected to commence in the second half of 2023.
Read more →AUTLAutolus Announces Partial Exercise of Underwriters Option to Purchase Additional ADSs LONDON 21 December 2022 Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation
Autolus Announces Partial Exercise of Underwriters Option to Purchase Additional ADSs LONDON 21 December 2022 Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced today that the und
Read more →AUTLAutolus Announces Pricing of Public Offering LONDON 8 December 2022 Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announ
Autolus Announces Pricing of Public Offering LONDON 8 December 2022 Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the pricing of its previously announced underwritten p
Read more →AUTLTAXATION The following summary contains a description of material U.K. and U.S. federal income tax consequences of the acquisition, ownership and disposition of our ADSs. This summary should not be considered a comprehen
The following summary contains a description of material U.K. and U.S. federal income tax consequences of the acquisition, ownership and disposition of our ADSs. This summary should not be considered a comprehensive description of all the tax considerations that may be relevant
Read more →AUTLof this Report on Form 6-K. 13
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of our financial condition and results of operations should be read together with the unaudited condensed consolidated financial statements and the related
Read more →AUTL▼ -6.9%on this news
THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to the action to be taken, please seek your own financial advice from your stockbroker, solicitor, accountant or other appropri
THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to the action to be taken, please seek your own financial advice from your stockbroker, solicitor, accountant or other appropriately authorised independent financial adviser. If you hav
Read more →AUTLof this Report on Form 6-K. 10
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of our financial condition and results of operations should be read together with the unaudited condensed consolidated financial statements and the related
Read more →AUTLAutolus Therapeutics announces retirement of chief financial officer and succession plan - Andrew J. Oakley to retire in March 2022 - Dr. Lucinda Crabtree to succeed him as chief financial officer LONDON
Autolus Therapeutics announces retirement of chief financial officer and succession plan - Andrew J. Oakley to retire in March 2022 - Dr. Lucinda Crabtree to succeed him as chief financial officer LONDON, January 10, 2022 Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-sta
Read more →AUTLAutolus Therapeutics announces the appointment of Dr. William D. Young as a Non-Executive Director LONDON
Autolus Therapeutics announces the appointment of Dr. William D. Young as a Non-Executive Director LONDON, November 15, 2021 Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announc
Read more →AUTL▲ +25.4%on this news
SECURITIES PURCHASE AGREEMENT This S ECURITIES P URCHASE A GREEMENT (this Agreement ) is made and entered into as of
SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this Agreement ) is made and entered into as of November 6, 2021 by and among AUTOLUS THERAPEUTICS PLC (registered number 11185179), a public limited company incorporated in England and Wales whose registered of
Read more →AUTL▲ +7.4%on this news· ran to +26% by day 3shared move
of this Report on Form 6-K. 18
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of our financial condition and results of operations should be read together with the unaudited condensed consolidated financial statements and the related
Read more →AUTLAutolus Therapeutics announces the appointment of John H. Johnson as non-executive chairman of its Board of Directors LONDON
Autolus Therapeutics announces the appointment of John H. Johnson as non-executive chairman of its Board of Directors LONDON, September 15, 2021 Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell the
Read more →AUTLof this Report on Form 6-K. 17
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of our financial condition and results of operations should be read together with the unaudited condensed consolidated financial statements and the related
Read more →AUTLAnnual Report and Accounts
Registered Number 11185179 (England & Wales) Annual Report and Accounts the year ended 31 December 2020 Autolus Therapeutics pie AUTOLUS THERAPEUTICS PLC Introduction and Contents Autolus Therapeutics pie (the Company , or Parent Company ) is a public limited company incor
Read more →AUTLAutolus Therapeutics announces appointment of Martin Murphy as Non-executive Chairman LONDON
Autolus Therapeutics announces appointment of Martin Murphy as Non-executive Chairman LONDON, April 19, 2021 Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that Dr Mart
Read more →AUTLAutolus Announces Proposed Public Offering in the United States LONDON 8 February 2021 Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell ther
Autolus Announces Proposed Public Offering in the United States LONDON 8 February 2021 Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it has commenced an underwritt
Read more →AUTLAutolus Therapeutics presents compelling AUTO1 data from ALLCAR Phase 1 study in Adult Acute Lymphoblastic Leukemia (ALL) during the 62nd ASH Annual Meeting Updated data from the ALLCAR study suggests AUTO1 s potential f
Autolus Therapeutics presents compelling AUTO1 data from ALLCAR Phase 1 study in Adult Acute Lymphoblastic Leukemia (ALL) during the 62nd ASH Annual Meeting Updated data from the ALLCAR study suggests AUTO1 s potential for transformational activity in adult patients with r/r A
Read more →AUTLof this Report on Form 6-K. 16
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of our financial condition and results of operations should be read together with the unaudited condensed consolidated financial statements and the related
Read more →AUTLAutolus Therapeutics presents additional data on AUTO3 in DLBCL during the ESMO Virtual Congress 2020 - AUTO3 shows promise of a highly differentiated product profile Conference call and webcast to be held Friday
Autolus Therapeutics presents additional data on AUTO3 in DLBCL during the ESMO Virtual Congress 2020 - AUTO3 shows promise of a highly differentiated product profile Conference call and webcast to be held Friday, September 18, 2020 at 8:00 am EDT / 1:00 pm BST LONDON, Septem
Read more →AUTLAutolus announces changes to its Board and Management Team
Autolus announces changes to its Board and Management Team Backstrom appointed to board of directors LONDON, Aug. 04, 2020 (GLOBE NEWSWIRE) Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapie
Read more →AUTLINDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Condensed Consolidated Balance Sheets as of
INDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Condensed Consolidated Balance Sheets as of March 31, 2020 and December 31, 2019 (Unaudited) F-2 Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three Months Ended March 31, 2020 and 2019 (Unaudi
Read more →AUTLAutolus Therapeutics Presents Encouraging Additional Data Showcasing Clinical Progress of Programmed T Cell Therapy Pipeline in Blood Cancers - Initial data show encouraging clinical activity with manageable safety profi
Autolus Therapeutics Presents Encouraging Additional Data Showcasing Clinical Progress of Programmed T Cell Therapy Pipeline in Blood Cancers - Initial data show encouraging clinical activity with manageable safety profile - No neurotoxicity observed to date in patients treate
Read more →AUTLAutolus Announces Proposed Public Offering in the United States LONDON 22 January 2020 Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell ther
Autolus Announces Proposed Public Offering in the United States LONDON 22 January 2020 Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it has commenced an offering o
Read more →AUTLAutolus Announces Pricing of Public Offering LONDON 10 April 2019 Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announce
Autolus Announces Pricing of Public Offering LONDON 10 April 2019 Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the pricing of an underwritten public offering in the Un
Read more →AUTLAutolus Announces Proposed Public Offering in the United States LONDON, UK
Autolus Announces Proposed Public Offering in the United States LONDON, UK, April 8, 2019 Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it intends to offer and sel
Read more →AUTLInitial Results from Autolus Therapeutics ALLCAR19 Phase 1/2 Trial in Adult Acute Lymphoblastic Leukemia Presented at the AACR Annual Meeting Initial results from the trial show 88% molecular complete response at one mon
Initial Results from Autolus Therapeutics ALLCAR19 Phase 1/2 Trial in Adult Acute Lymphoblastic Leukemia Presented at the AACR Annual Meeting Initial results from the trial show 88% molecular complete response at one month with well-tolerated safety profile Management to Hold
Read more →AUTLAutolus Therapeutics Unveils Expanded Next Generation Technology and Pipeline and Provides Key Update on AUTO3 Program in Pediatric ALL at R&D Day Program and webcast today
Autolus Therapeutics Unveils Expanded Next Generation Technology and Pipeline and Provides Key Update on AUTO3 Program in Pediatric ALL at R&D Day Program and webcast today, March 26, 2019 at 8:00 am ET LONDON, UK, March 26, 2019 Autolus Therapeutics plc (Nasdaq: AUTL), a clin
Read more →AUTLAutolus Therapeutics Reports Financial and Operational Results for the Transition Period from October 1 to
Autolus Therapeutics Reports Financial and Operational Results for the Transition Period from October 1 to December 31, 2018 - Conference Call to be held on February 25, 2019 at 8:00 am EST/12:00 pm GMT - LONDON, February 25, 2019 Autolus Therapeutics plc (Nasdaq: AUTL), a cli
Read more →AUTLAutolus Therapeutics Presents Initial AUTO3 Clinical Data from Phase 1/2 Clinical Trials in B cell Malignancies at the 60 th ASH Annual Meeting - Initial results were presented from ongoing Phase 1/2 trials in pediatric
Autolus Therapeutics Presents Initial AUTO3 Clinical Data from Phase 1/2 Clinical Trials in B cell Malignancies at the 60th ASH Annual Meeting - Initial results were presented from ongoing Phase 1/2 trials in pediatric acute lymphoblastic leukemia (AMELIA trial) and diffuse B
Read more →AUTLAUTOLUS THERAPEUTICS PLC (formerly AUTOLUS THERAPEUTICS LIMITED) BALANCE SHEET (UNAUDITED) (Expressed in US Dollars, unless otherwise stated)
AUTOLUS THERAPEUTICS PLC (formerly AUTOLUS THERAPEUTICS LIMITED) in US Dollars, unless otherwise stated) March 31, 2018 TOTAL ASSETS $ Liabilities Equity Share capital ( 0.00001 par value, one hundred thousand shares, issued and outstanding) 1 Additional paid
Read more →Competitive Position
How AUTL ranks across every disease it competes inCompetitive Position is a premium feature
See how AUTL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial